Vaccine Preventable Diseases
Advisory Committee on Immunization Practices (ACIP) Recommendations
All Age Groups
• All persons without contraindications who are 6 months of age and older should receive annual vaccination with influenza vaccine.
• Inactivated influenza vaccine (abbreviation: IIV; trade names: see the table on the following pages) is recommended for all age groups and during pregnancy .
• Live attenuated influenza vaccine (abbreviation: LAIV; trade name: FluMist®) is also an option for non-pregnant persons between 2 and 49 years of age .
• Influenza vaccine should be given as soon as it becomes available (usually between August and October in the U.S.) in order to ensure the highest possible level of protection before rates of transmission increase. Peak transmission season is usually between December and March in the United States .
Infants and Children
• Children younger than 9 years of age receiving IIV for the first time ever should receive two doses at least one month apart; otherwise, one dose per year is sufficient .
For More Information
• ACIP recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html
• Immunization schedules: http://www.cdc.gov/vaccines/schedules/index.html
Influenza is caused by RNA viruses of three types. Type A influenza is the cause of most human illness and has many subtypes based on the variations in the surface antigens (i.e., hemagglutinin (H) and neuraminidase (N)), such as H1N1 or H3N2. Type B influenza also infects humans but generally causes milder illness. Type C only very rarely causes human disease.
The surface antigens on influenza viruses are always evolving, faster than most other viruses that cause human disease. This continuous stream of minor mutations is called antigenic drift and is what makes influenza so adept at evading immunity induced by prior infection or vaccination. In most years, at least some of the circulating influenza strains have drifted compared to prior years, thus even those who were infected or vaccinated in years prior may develop influenza disease again.
Occasionally a major change in one or both surface antigens occurs, known as antigenic shift; the majority of the population is usually susceptible to the new virus. The new strains generated in this manner, such as the 2009 influenza A H1N1, have the potential to cause a worldwide pandemic .
The incubation period for influenza is generally 2 days. The major clinical symptoms typically last a median of 4 days without treatment and include sore throat, fever, headache, myalgia, and nonproductive cough. Pneumonia is the most common complication of influenza. Other complications include Reye syndrome and myocarditis [3, 4].
Pregnant women, young children, elderly adults, and persons with pre-existing medical conditions are at increased risk of complications and hospitalizations from influenza [5-7]. There was an average of 113 annual pediatric deaths from influenza in the United States between 2010 and 2016, and about half of these were in children with no preexisting medical condition .
The CDC estimated an average of 23,607 annual influenza-associated deaths in the United States between 1976 and 2007 among all age groups, although these estimates ranged widely from year to year . Studies have also estimated an average of approximately 130,000 annual influenza-associated hospitalizations in the United States [6, 10].
Two types of vaccines are available to protect against influenza: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). LAIV (trade name: FluMist®) was not recommended for use during the 2016-2017 or 2017-2018 flu seasons due to problems with low effectiveness during the previous several seasons, but is again an option for the 2018-2019 season for non-pregnant persons 2-49 years of age for whom it is otherwise appropriate
. LAIV is administered intranasally using a single dose sprayer containing 0.2 mL, with about half (0.1 mL) sprayed in each nostril [1-3].
In the United States, quadrivalent IIV (IIV4) vaccines include Fluarix® Quadrivalent, FluLaval® Quadrivalent, and Fluzone® Quadrivalent; trivalent IIV (IIV3) include Afluria®, Fluvirin®, and Fluzone®. There are two recombinant influenza vaccines, Flublok® (RIV3) and Flublok® Quadrivalent (RIV4). Trivalent vaccines contain one A/H3N2 strain, one A/H1N1 strain, and one B strain from one of the two B lineages (Yamagata and Victoria). The Quadrivalent vaccines contain a second B strain [1,3].
The Food and Drug Administration (FDA) has recommended that the trivalent influenza vaccines used in the United States during the 2018-19 season contain an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus, and a B/Colorado/06/2017-like (B/Victoria lineage) virus; and that the quadrivalent vaccines also contain a B/Phuket/3073/2013-like (B/Yamagata lineage) virus .
Inactivated Influenza Vaccine (IIV)
|Route of administration: Primarily intramuscular (IM), one intradermal (ID); specified for each vaccine listed below.|
|Vaccine Virus: Inactivated, split or subvirion.
|Trade Name||Dose Available||Age Range Approved|
|Fluzone® Quadrivalent||0.25 mL prefilled syringe or
5.0 mL multi-dose vial (IM)
|≥ 6-35 months of age|
|Fluzone® Quadrivalent||0.5 mL single-dose vial or
prefilled syringe or
5.0 mL multi-dose vial (IM)
|≥ 36 months of age|
|Fluzone® Quadrivalent||5.0 mL multi-dose vial (IM)||≥ 6 months of age|
|Fluarix® Quadrivalent||0.5 mL single-dose prefilled syringe (IM)||≥ 6 months of age|
|FluLaval® Quadrivalent||5.0 mL multi-dose vial (IM)||≥ 6 months of age|
|Flucelvax® Quadrivalent||0.5 mL single-dose prefilled syringe (IM)||≥ 4 years of age|
|Afluria®||0.5 mL single-dose prefilled syringe or
5.0 mL multi-dose vial (IM)
|≥ 5 years of age|
|Afluria® Quadrivalent||0.5 mL prefilled syringe (IM)||> 5 years of age|
|Afluria® Quadrivalent||5.0 mL multi-dose vial (IM)||5 years of age (by needle/syringe)
18-64 years of age (by jet injector)
|Fluvirin®||0.5 mL single-dose prefilled syringe or
5.0 mL multi-dose vial (IM)
|≥ 4 years of age|
|Fluad®||0.5 mL single-dose prefilled syringe (IM)||≥ 65 years of age|
|Fluzone® High-Dose||0.5 mL single-dose prefilled syringe (IM)||≥ 65 years of age|
|Flublok®||0.5 mL single-dose vial (IM)||≥ 18 years of age|
|Flublok® Quadrivalent||0.5 mL single-dose vial (IM)||>18 years of age|
|Flublok® Quadrivalent||0.5 mL single-dose vial (IM)||≥ 18 years of age|
|Fluzone® Intradermal Quadrivalent||0.1 mL single-dose prefilled microinjection system) (ID)||18-64 years of age|
Vaccine Effectiveness: The effectiveness of influenza vaccines varies each year in relation to the match between the vaccine strains and the circulating strain. Effectiveness can also vary by the age and health status of the vaccine recipient . Effectiveness has been shown to decline significantly over the first six months post-vaccination, albeit at different rates depending on the vaccine [16-18]. However, even in years when the vaccine has a lower effectiveness relative to other years, receiving the vaccine still reduces risk of infection, severe illness, hospitalization, and death due to influenza. In addition, high vaccine coverage prevents disease transmission and helps to protect those most vulnerable to serious influenza illness .
Vaccine Safety: Common adverse reactions to IIV include local reactions such as soreness, erythema and induration at the injection site, which are reported at variable rates, but are usually mild and typically last no more than 2 days. Systemic symptoms such as sensation of fever, chills, malaise, and myalgia are also common. These symptoms typically begin within 6–12 hours of vaccination and usually last for only a few hours. Such symptoms are usually mild but have been reported in 4-<30% of children receiving IIV [20-26]. Myalgia within a week of vaccination has been reported among 14-16% of adults receiving unadjuvanted IIV and 31-39% of adults receiving adjuvanted IIV , with even higher rates among recipients of the 2009 pandemic H1N1 vaccine .
Rarely, allergic reactions such as hives, angioedema, allergic asthma, or systemic anaphylaxis occur after vaccination, probably due to hypersensitivity to a vaccine component. See the Do Vaccines Cause Hypersensitivity Reactions? summary for more details.
Influenza vaccination in recent years has been associated with a very small increased risk of GBS in adults, leading to about 1-3 excess cases of GBS per million persons vaccinated. This is much less than the estimated risk after wild-type influenza infection, providing further evidence that the benefits of influenza vaccination greatly outweigh the risks [29,30]. See the Do Vaccines Cause Guillain-Barré Syndrome (GBS)? summary for more details.
IIV cannot cause influenza, as all viruses contained in the vaccine are inactivated and noninfectious . LAIV also cannot cause influenza as it is made from weakened flu virus .
Contraindications and Precautions: An important contraindication is having had a severe allergic reaction (e.g. anaphylaxis) to a vaccine component or previous vaccination. However, this does not include egg allergies, even though most influenza vaccines are grown in embryonated chicken eggs (an exception being the egg-free recombinant influenza vaccine, Flublok®) . This is because the vaccines marketed in the United States have been found to contain extremely small amounts or undetectable amounts of egg protein and recent studies have indicated that egg allergic patients can safely receive influenza vaccines [12, 13]. The ACIP recommends that persons with a severe egg allergy (who have had associated angioedema, respiratory distress, lightheadedness, or recurrent emesis, or who required epinephrine or another emergency medical intervention following egg ingestion) can receive these vaccines, but the vaccine should be administered in an inpatient or outpatient medical setting . However, the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American Academy of Pediatrics (AAP) do not recommend any special precaution because there does not appear to be any increased risk of severe allergic reactions to these vaccines in persons with egg allergy [14,15].
Precautions include moderate to severe acute illness with or without fever, as well as a diagnosis of Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of influenza vaccine .
Precautions include moderate to severe acute illness with or without fever, as well as a diagnosis of Guillain-Barré Syndrome (GBS) within 6 weeks after a previous dose of influenza vaccine .
The complete current recommendations of the ACIP regarding influenza vaccine delivery can be found at the following website: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html.
Considerations in Pregnancy:
• Inactivated influenza vaccine (IIV) is routinely recommended during pregnancy.
• Live attenuated influenza vaccine (LAIV) is contraindicated during pregnancy .
Pregnant women and young children are at increased risk of complications and hospitalizations from influenza. Infection with influenza during pregnancy has been associated with an increased risk of adverse outcomes to the mother including respiratory hospitalization, pneumonia, adult respiratory distress syndrome, overwhelming sepsis and death . A recent CDC study estimated that 12% of all pregnancy-related deaths during the 2009-2010 pandemic season were attributed to confirmed or possible infection with pandemic influenza .
IIV was shown to reduce non-specific febrile respiratory illness in pregnant women by over one third. Vaccine effectiveness was most pronounced during influenza season. Vaccination in pregnancy is beneficial not just for the mother, but for her unborn child as well. Maternal influenza vaccination was shown in one study to reduce proven influenza illness in infants under 6 months of age by up to 63% . In several other studies, IIV was shown to reduce the risk of low birthweight and premature birth [35, 36]. Some studies have found that pregnant women who received influenza vaccine had a lower likelihood of stillbirth than those who did not [37-39], although the evidence for this is inconsistent and has methodological limitations [39-41].
A large body of evidence demonstrates the safety of IIV for both pregnant women and their unborn children [42-48]. Concomitant administration of Tdap and influenza vaccines during pregnancy is not associated with a higher risk of adverse outcomes compared to sequential vaccination . .
Donahue et al. recently reported results from a case-control study examining the risk of spontaneous abortion (SAb) following receipt of inactivated influenza vaccines containing A/H1N1pdm2009 antigen in the 2010-11 and 2011-12 seasons . The study found an association between influenza vaccine and SAb, particularly among women who had received pandemic H1N1 vaccine in the previous year as well . The findings were most striking in the 2010-2011 season, and were far less pronounced in the 2011-2012 season. The Donahue et al. findings need to be interpreted in the context of other epidemiological data . One recent randomized trial recruiting women at 17-34 weeks gestation , thirteen other observational studies [53-65], two systematic reviews [46, 66], and one meta-analysis  have assessed a potential association between influenza vaccine and SAb or a related outcome, and none have found an association. However, none of these studies examined the effect of multiple dosing. Studies are in progress to assess whether this association is seen in subsequent influenza seasons. See the Do Vaccines Cause Spontaneous Abortion? summary for more details.
1. Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. MMWR Recomm Rep 2017;66(2):1-20.
2. Grohskopf, L.A., et al., Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. MMWR Morb Mortal Wkly Rep 2018;67(22):643-5.
3. Epidemiology and Prevention of Vaccine-Preventable Diseases, K.A. Hamborsky J, Wolfe S Editor. 2015, Centers for Disease Control and Prevention: Washington D.C.
4. Fry AM, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014;14(2):109-18.
5. Tamma PD, Steinhoff MC, Omer SB. Influenza infection and vaccination in pregnant women. Expert Rev Respir Med 2010;4(3):321-8.
6. Kostova D, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. PLoS One 2013;8(6):e66312.
7. Centers for Disease Control and Prevention. People at High Risk of Developing Flu–Related Complications. 2018 [cited 2018 March].
8. Shang M, et al. Influenza-Associated Pediatric Deaths in the United States, 2010–2016. Pediatrics;2018.
9. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59(33):1057-62.
10. Thompson WW, et al. Influenza-associated hospitalizations in the United States. Jama 2004;292(11):1333-40.
11. Centers for Disease Control and Prevention. Influenza Vaccines. in Meeting of the Advisory Committee on Immunization Practices (ACIP). June 2018. Atlanta, GA.
12. Greenhawt MJ, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol 2012;109(6):426-30.
13. Greenhawt MJ, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. Annals of Allergy, Asthma & Immunology 2018;120(1)49-52.
14. American Academy of Allergy Asthma and Immunology. Egg Allergy and the Flu Vaccine. Last accessed May 2018.
15. Dreskin SC, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J 2016; 9(1):32.
16. Young B, et al. Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. J Infect Dis 2018;217(5):731-41.
17. Clements ML, et al. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986;23(1):73-6.
18. Belshe RB, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356(7):685-96.
19. Centers for Disease Control and Prevention. Vaccine Effectiveness - How Well Does the Flu Vaccine Work? 2017. Last Accessed 2018 June.
20. Brady RC, et al. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. Vaccine 2014;32(52):7141-7.
21. Greenberg DP, et al. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J 2014;33(6):630-6.
22. Baxter R, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010;29(10):924-30.
23. Nolan T, et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses 2009;3(6):315-25.
24. Domachowske JB, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013;207(12):1878-87.
25. Langley JM, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013;208(4):544-53.
26. Tregnaghi MW, et al. Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study. Viral Immunol 2012;25(3):216-25.
27. Beran J, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013;13:224.
28. Nicholson KG, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011;11(2):91-101.
29. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 2014;58(8):1149-55.
30. Salmon DA, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013;381(9876):1461-8.
31. Centers for Disease Control and Prevention. Misconceptions about Seasonal Flu and Flu Vaccines. 2017. Last Accessed 2018 June.
32. Centers for Disease Control and Prevention, Vaccine Information Statement - Live Attenuated Influenza Vaccine. 2015.
33. Callaghan WM, Creanga AA, Jamieson DJ. Pregnancy-Related Mortality Resulting From Influenza in the United States During the 2009-2010 Pandemic. Obstet Gynecol 2015;126(3):486-90.
34. Zaman K, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359(15):1555-64.
35. Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol 2012;207(3 Suppl):S3-8.
36. Phadke VK, Omer SB. Maternal vaccination for the prevention of influenza: current status and hopes for the future. Expert Rev Vaccines 2016;15(10):1255-80.
37. Bratton KN, et al. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 2015;60(5):e11-9.
38. Regan AK, et al. Seasonal Trivalent Influenza Vaccination During Pregnancy and the Incidence of Stillbirth: Population-Based Retrospective Cohort Study. Clin Infect Dis 2016;62(10):1221-7.
39. Fell DB, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG: An International Journal of Obstetrics & Gynaecology 2015;122(1):17-26.
40. Fell DB, et al. Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. Vaccine 2017;35(18):2279-87.
41. Savitz DA, et al. Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. Vaccine 2015;33(47):6430-5.
42. Tamma PD, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009;201(6):547-52.
43. Bednarczyk RA, Adjaye-Gbewonyo D, Omer SB. Safety of influenza immunization during pregnancy for the fetus and the neonate. Am J Obstet Gynecol 2012;207(3 Suppl):S38-46.
44. Keller-Stanislawski B, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 2014;32(52):7057-64.
45. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec, 2012. 87(47): p. 461-76.
46. McMillan M, et al. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015;33(18):2108-17.
47. Polyzos KA, et al. Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. Obstet Gynecol 2015;126(5):1075-84.
48. Kharbanda EO, et al., Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. Obstet Gynecol 2013;122(3):659-67.
49. Sukumaran L, et al. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol 2015;126(5):1069-74.
50. Donahue JG, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine 2017;35(40):5314-22.
51. Chambers CD, R. Xu, and A.A. Mitchell, Commentary on: "Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12". Vaccine 2017;35(40):5323-24.
52. Steinhoff MJ, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis 2017;17(9):981-9.
53. Chambers CD, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 2013;31(44):5026-32.
54. Chambers CD, et al. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine 2016;34(37):4443-9.
55. Chavant F, et al. The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza. Drug Safety 2013;36(6):455-65.
56. Huang WT, et al., Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine 2014;32(48):6463-8.
57. Ludvigsson JF, et al. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ 2015;351:h5585.
58. Ma F, et al. Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol 2014;21(9):1282-7.
59. Oppermann M, et al. A(H1N1)v2009: A controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012;30(30):4445-52.
60. Pasternak B, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ : British Medical Journal 2012;344.
61. Tavares F, et al. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: A prospective cohort study. Vaccine 2011;29(37):6358-65.
62. Irving SA, et al. Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion. Obstetrics & Gynecology 2013;121(1):159-65.
63. Sammon CJ, et al. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One 2012;7(12):e51734.
64. Heikkinen T, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol, 2012;207(3)177.e1-8.
65. de Vries L, et al. Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands. Birth Defects Res A Clin Mol Teratol 2014;100(10):731-8.
66. Bednarczyk RA, Adjaye-Gbewonyo D, Omer SB. Safety of influenza immunization during pregnancy for the fetus and the neonate. American Journal of Obstetrics & Gynecology 2012;207(3):S38-46.